Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novartis Licenses T Cell Technology
by Michael McCoy
October 20, 2014
| A version of this story appeared in
Volume 92, Issue 42
Novartis will pay the English firm Oxford BioMedica $14 million up front and possibly $90 million more over the next three years for a nonexclusive license to OXB’s viral vector technology. OXB will manufacture gene-carrying vectors for Novartis. Novartis, in turn, will use OXB’s technology to insert the instructions for a chimeric antigen receptor into the white blood cells known as T cells. T cells, so enhanced to home in on cancer, are the basis of a Novartis immunotherapy called CTL019/CART-019 (C&EN, Oct. 6, page 12).
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter